FDA Post-CRL Resubmissions: Type A Meetings and Class 1 vs Class 2 Clocks

Type A Post-Action Meetings vs Type B End-of-Review Meetings Under PDUFA VII

After receiving an action letter under 21 CFR 314.110 (NDAs) or 21 CFR 601.3 (BLAs), applicants seek formal alignment with CDER or CBER before spending capital on remediation work FDA might reject.

Under the FDA Draft Guidance on Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (September 2023) and the PDUFA VII Commitment Letter for FY 2023–2027, meeting tiers impose exact statutory targets:

• Type A Meetings (Stalled Development / Post-CRL): Reserved to help a stalled development program proceed. Crucially, to qualify as a Type A post-action meeting, the applicant must submit the meeting request within 3 months of FDA's CRL issuance date—and must include the complete briefing package simultaneously with the meeting request.
  • Scheduling Target: Within 30 calendar days of receipt of the Type A request.
  • Official FDA Minutes: Issued within 30 calendar days after the meeting (or within 30 days of request receipt if Written Responses Only [WRO] are granted).
• The Post-90-Day Downgrade Trap (Type B / Type C): If a sponsor needs four or five months to investigate manufacturing root causes or re-analyze clinical data before requesting its post-CRL meeting, it misses the 3-month Type A cutoff. FDA generally reclassifies late requests as Type B (60-day scheduling clock) or Type C (75-day clock), immediately adding 30 to 45 days before formal dialogue begins.
• Type D Meetings (50-Day Narrow-Topic Pathway): Introduced under PDUFA VII for ≤2 focused questions spanning no more than three review disciplines, occasionally used after an initial Type A meeting to confirm narrow assay or comparability details prior to resubmission.

Remember what Type A minutes do and do not establish: official minutes record agency feedback on whether a proposed remediation plan looks reasonable on paper, not pre-approval of the resulting data or facility re-inspection. When a press release states "productive Type A meeting held" without disclosing specific deliverables or stability/inspection requirements, keep remediation scope UNKNOWN.

Class 1 (2-Month) vs Class 2 (6-Month) Resubmission Classification Rules

The costliest misconception in biotech catalyst trading is assuming "CMC-only CRL = Class 1 (2-month review)" and "Clinical CRL = Class 2 (6-month review)." Agency procedures directly refute that shortcut.

Under 21 CFR 314.110(b)(1), PDUFA VII goals, CDER MAPP 6020.4, and CBER SOPP 8405.1, Class 1 is narrowly limited to minor items requiring zero facility inspection and no complex re-analysis:

Items Qualifying for Class 1 (2-Month PDUFA Goal)

• Draft or final printed labeling negotiations;
• Safety updates summarizing unchanged clinical safety profiles without complex new analyses;
• Stability extensions on existing batches confirming previously reviewed specifications;
• Phase 4 postmarketing study commitments;
• Bounded assay clarifications or minor re-analyses of previously submitted datasets without process modifications.

Items Automatically Triggering Class 2 (6-Month PDUFA Goal)

Any item outside the narrow Class 1 list—or any resubmission requiring an on-site facility inspection or follow-up Pre-Approval Inspection (PAI) verification—falls into Class 2 (6-month PDUFA goal):

• Any cGMP or contract manufacturer (CDMO) remediation requiring an FDA re-inspection or extensive Corrective and Preventive Action (CAPA) assessment;
• Transfer to a new drug-substance or sterile fill-finish facility;
• Substantial CMC process changes, comparability protocols, or new commercial validation batches;
• New clinical efficacy/safety data, complex exposure-response modeling, or major REMS structural revisions.

Consequently, most PAI and manufacturing CRLs receive Class 2 (6-month) designations upon resubmission, not Class 1! FDA communicates the official Class 1 or Class 2 designation and target date in its Resubmission Acknowledgment Letter (~14 to 30 calendar days after resubmission receipt). Until that acknowledgment letter is confirmed, review class and goal date remain UNKNOWN.

The 1-Year Resubmission Rule, Incomplete Responses, and Major Amendments

Three statutory friction points routinely stretch post-CRL timelines beyond consensus models:

1. 12-Month Action Deadline (21 CFR 314.110(b)–(c)): Within one year of a CRL, an applicant must resubmit a complete response, withdraw the application without prejudice, or request a formal extension; inaction allows FDA to deem the application withdrawn.
2. Incomplete Response Letters ("Clock Refusal"): Under CDER/CBER policy, a resubmission must address every single deficiency in the CRL, and any facility needing re-inspection must be inspection-ready at submission. Rushing an incomplete eCTD package triggers an Incomplete Response letter: the PDUFA review clock does not start until missing items arrive.
3. 3-Month Major Amendment Extensions: Filing substantial new stability batches or clinical analyses mid-review allows FDA to extend a Class 1 or Class 2 goal date by 3 additional months (stretching Class 2 to 9 months).

Reconciling Management Headlines Against SEC Form 8-K and Cash Runway Buffers

FDA releases redacted CRLs for unapproved applications only selectively (see openFDA CRL Documentation and our CRL verification guide), while SEC Rule 10b-5 governs material omissions in SEC EDGAR Form 8-K disclosures (Item 8.01, or Items 1.01/2.04 if a CRL triggers debt defaults).

When auditing a post-CRL biotech:

• Check Debt Covenants Immediately: Many venture-debt agreements tie Tranche B/C funding, interest-only windows, or minimum-cash covenants to NDA/BLA approval by a fixed date—potentially trapping liquidity as restricted cash (see our restricted cash guide).
• Stress-Test Realistic Cash Burn: Combining 1 month for Type A briefing + 1 month for Type A meeting + 3 months of CMC CAPA execution + 6 months of Class 2 review adds 11 months of operating burn before potential approval. Stress-test that window in BioSniper's Cash Runway Calculator, inspect low-buffer issuers on the Biotech Cash Runway Report, and track confirmed goal dates on the PDUFA Calendar.